Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

NCT04965935 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Recipients
Post-transplant Diabetes Mellitus
Type 2 Diabetes

Interventions

DRUG: Dapagliflozin 10 MG Oral Tablet
DRUG: Placebo Matching Dapagliflozin Oral Tablet

Sponsor

University Health Network, Toronto